Related Experiment Video
Updated: Nov 30, 2025
Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice
Published on: April 15, 2014
Titration of myelin oligodendrocyte glycoprotein (MOG) - Induced experimental autoimmune encephalomyelitis (EAE)
Rina Aharoni1, Renana Globerman1, Raya Eilam2
1Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel.
Background:
Experimental autoimmune encephalomyelitis (EAE) induced by the myelin oligodendrocyte glycoprotein (MOG) peptide 35-55, is a widely used multiple sclerosis (MS) model. Unlike the spontaneous occurrence of MS, in EAE, external immunization with the MOG peptide (200-300 µg/mouse), emulsified in adjuvant enriched with Mycobacterium Tuberculosis (MT) H37Ra (100-500 µg mouse), and pertussis toxin (PTx, 200-500 ng/mouse) injections, are applied, which heavily boosts the immune system.
New Method:
A detailed and systematic titration of the MOG 35-55 EAE induction protocol in C57BL/6 mice reveals the minimal doses of the MOG 35-55 peptide, MT H37Ra, and PTx, required for disease manifestation.
Results:
The amounts of MOG 35-55 peptide, MT H37Ra, and PTx can be drastically reduced from the standard protocol, to level of 5 µg MOG, 25 µg MT H37Ra, and 50 ng PTx, without affecting the clinical manifestations. The titrated protocols induced a high disease incidence and a consistent robust disease course, with full histopathological characteristics of the MOG model, inflammation, demyelination and axonal damage.
Comparison With Existing Methods:
Similar disease incidences, day of symptoms appearance, maximal clinical score, and histopathology were obtained for the standard and the titrated protocols.
Conclusions:
Reducing the reagent dosages used for EAE induction, without attenuating the disease, can give a truer and less artificial perspective of MS. We propose an improved protocol for this extensively used model, with high disease incidence, a consistent robust course, and characteristic histological manifestations, which may be more sensitive for testing therapeutic modalities, cost-effective, and less distressing to the animals.
Insights
This study optimized the MOG peptide 35-55 induced experimental autoimmune encephalomyelitis (EAE) model for multiple sclerosis (MS) research. Reduced reagent doses maintain disease severity, offering a more sensitive and ethical animal model.
Area of Science:
- Neuroscience
- Immunology
- Animal Models
Background:
- Experimental autoimmune encephalomyelitis (EAE) is a key animal model for multiple sclerosis (MS).
- Standard EAE induction involves high doses of myelin oligodendrocyte glycoprotein (MOG) peptide 35-55, Mycobacterium tuberculosis (MT) H37Ra, and pertussis toxin (PTx).
- These high doses create an artificial immune boost, potentially confounding research findings.
Purpose of the Study:
- To systematically determine the minimal effective doses of MOG peptide 35-55, MT H37Ra, and PTx for EAE induction in C57BL/6 mice.
- To develop a refined EAE protocol that reduces reagent usage while maintaining disease fidelity.
- To enhance the model's sensitivity for therapeutic testing and improve animal welfare.
Main Methods:
- Systematic titration of MOG peptide 35-55, MT H37Ra, and PTx dosages.
- Induction of EAE in C57BL/6 mice using standard and titrated protocols.
- Clinical scoring and histopathological analysis (inflammation, demyelination, axonal damage) to compare disease outcomes.
Main Results:
- Significantly reduced doses (5 µg MOG, 25 µg MT H37Ra, 50 ng PTx) effectively induced EAE.
- The titrated protocol resulted in high disease incidence and consistent, robust disease courses.
- Histopathology, clinical scores, and symptom onset were comparable to the standard protocol.
Conclusions:
- Reduced reagent dosages in the MOG 35-55 EAE model do not attenuate disease severity.
- The optimized protocol provides a more accurate and less artificial representation of MS.
- This refined EAE model is more cost-effective, ethically sound, and potentially more sensitive for evaluating MS therapeutics.
More Related Videos
10:47Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies
Published on: October 27, 2016
05:55Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
Published on: December 1, 2023